1 Medical University Graz, Austria.
2 Auckland City Hospital, Auckland, New Zealand.
J Endovasc Ther. 2018 Aug;25(4):499-503. doi: 10.1177/1526602818783989. Epub 2018 Jun 18.
To evaluate the safety and feasibility of treating calcified infrapopliteal stenoses using an intravascular lithotripsy (IVL) system.
The Disrupt BTK study was a prospective, nonrandomized, multicenter, feasibility, and safety trial that enrolled 20 patients (mean age 79.0±9.6 years; 14 men) at 3 participating sites ( ClinicalTrials.gov identifier NCT02911623). Fifteen patients had Rutherford category 5 ischemia, and all patients had moderate to severe below-the-knee arterial calcification. Patients were treated with the Shockwave Medical Peripheral IVL System and followed for 30 days. The primary safety endpoint was a composite of major adverse events through 30 days defined as death, myocardial infarction, need for emergency surgical revascularization of the target limb, or amputation of the target limb. The primary effectiveness outcome was acute reduction in the percent diameter stenosis.
IVL catheter delivery was successful in 19 patients. The composite of major adverse events at 30 days was 0%. The acute reduction in percent diameter stenosis of target lesions was 46.5%. All patients achieved residual diameter stenosis ≤50%. Vascular complications were minimal with only 1 type B dissection reported and 2 stents placed. None of the subjects experienced thrombus formation, abrupt closure, distal embolization, or perforation. There were no device-related complications.
The early results of this pilot study demonstrated that calcified, stenotic infrapopliteal arteries can be safely and successfully treated with intravascular lithotripsy.
评估使用血管内碎石术(IVL)系统治疗钙化性下肢动脉狭窄的安全性和可行性。
Disrupt BTK 研究是一项前瞻性、非随机、多中心、可行性和安全性试验,在 3 个参与地点(ClinicalTrials.gov 标识符 NCT02911623)招募了 20 名患者(平均年龄 79.0±9.6 岁;14 名男性)。15 名患者存在 Rutherford 5 级缺血,所有患者均有中度至重度膝下动脉钙化。患者接受 Shockwave Medical 外周 IVL 系统治疗,并随访 30 天。主要安全性终点是通过 30 天定义的主要不良事件的复合事件,定义为死亡、心肌梗死、目标肢体紧急手术血运重建或目标肢体截肢。主要有效性结果是急性靶病变狭窄程度百分比降低。
19 名患者成功进行了 IVL 导管输送。30 天时的主要不良事件复合发生率为 0%。靶病变的急性狭窄百分比降低 46.5%。所有患者的残余狭窄程度均≤50%。血管并发症很少,仅报告了 1 例 B 型夹层和 2 例支架置入。无患者发生血栓形成、急性闭塞、远端栓塞或穿孔。无器械相关并发症。
这项初步研究的早期结果表明,钙化性狭窄的下肢动脉可以安全且成功地通过血管内碎石术进行治疗。